| Literature DB >> 29497506 |
Johannes Mischlinger1,2,3,4, Luzia Veletzky1,2,4, Gildas B Tazemda-Kuitsouc5, Paul Pitzinger1,2, Pierre B Matsegui2,3,5, Markus Gmeiner2,3, Heimo Lagler1, Tamirat Gebru2,3, Jana Held2,3, Benjamin Mordmüller2,3, Michael Ramharter1,2,3,4.
Abstract
BACKGROUND: Loiasis is a vector-borne disease in Central and West Africa. While there is still uncertainty to what extent loiasis is responsible for population morbidity, individuals having both loiasis and onchocerciasis have a high risk of fatal encephalopathy when treatment (ie, ivermectin) for onchocerciasis is given. Therefore it is current policy that communities of high loiasis-burden are excluded from mass drug administration programmes of ivermectin. To address this treatment gap we present diagnostic scores, based on clinical and behavioural predictors that may help to rapidly identify sub-groups with loiasis within high-burden communities.Entities:
Mesh:
Year: 2018 PMID: 29497506 PMCID: PMC5827628 DOI: 10.7189/jogh.08.010413
Source DB: PubMed Journal: J Glob Health ISSN: 2047-2978 Impact factor: 4.413
Baseline characteristics
| Total cohort (N = 947) | Loiasis (n = 289) | Population of Calabar swelling sub-study (n = 213) | |
|---|---|---|---|
| No. (column %) | No. (row %) | No. (column %) | |
| Median (IQR) | 22 (8-51) | 51 (32-65) | 16 (7-40) |
| Below 6 | 160 (16.9%) | 2 (1.3%) | 44 (20.6%) |
| 6 to 17 | 272 (28.7%) | 26 (9.6%) | 65 (30.5%) |
| 18 to 34 | 147 (15.5%) | 52 (35.4%) | 37 (17.4%) |
| 35 to 49 | 120 (12.7%) | 60 (50%) | 27 (12.7%) |
| 50 to 64 | 113 (11.9%) | 65 (57.5%) | 13 (6.1%) |
| 65 or older | 135 (14.3%) | 84 (62.2%) | 27 (12.7%) |
| Male | 434 (45.8%) | 124 (28.6%) | 101 (47.4%) |
| None | 311 (32.8%) | 12 (3.9%) | 67 (31.5%) |
| Occasional | 237 (25%) | 42 (17.7%) | 76 (35.7%) |
| Frequent | 173 (18.3%) | 82 (47.4%) | 42 (19.7%) |
| Intensive | 226 (23.9%) | 153 (67.7%) | 28 (13.1%) |
| Positive | 245 (25.9%) | 245 (100%) | 46 (21.6%) |
| Positive | 101 (10.7%) | 101 (100%) | 24 (11.3%) |
| Positive | 289 (30.5%) | 289 (100%) | 60 (28.2%) |
| Positive | 306 (32.3%) | 206 (67.3%) | 42 (19.7%) |
| Positive | 13.3% (7.1-23.5)* | 10 (62.5%)† | 16 (7.5%) |
RAPLOA – rapid assessment procedure for Loa loa
*Percentage (95% CI) of history of Calabar swelling was estimated through direct standardization of results from the sub-study population (n = 213) using the age-structure of the whole population (N = 947).
†Calculated only for people with loiasis (n = 16) of sub-study population (n = 213).
Cross-tabulation of loiasis-defining characteristics*
| Total N = 947 | RAPLOA + (n, row %) | RAPLOA – (n, row %) |
|---|---|---|
| Microfilaraemia + | ||
| Microfilaraemia – | ||
RAPLOA – rapid assessment procedure for Loa loa
*χ2 test (P < 0.001).
Predictors for loiasis
| Predictors for loiasis | Loiasis (N = 289) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|
| Below 6 | 2 (1.3%)* | 1 | 1 |
| 6 to 17 | 26 (9.6%)* | 8.3 (1.9-36.4) | 7.9 (1.8-34.3)† |
| 18 to 34 | 52 (35.4%)* | 43.2 (8.7-215.8) | 36.1 (7.2-180.6)† |
| 35 to 49 | 60 (50%)* | 79 (13.4-464.8) | 57.9 (8.6 – 391.7)† |
| 50 to 64 | 65 (57.5%)* | 107 (16.2-708.6) | 69.8 (7.4 – 662.3)† |
| 65 or older | 84 (62.2%)* | 130.1 (18.8-901.6) | 73.9 (5.0 – 1099.9)† |
| Female | 165 (32.2%)‡ | 1 | 1 |
| Male | 124 (28.6%)‡ | 0.84 (0.6-1.1) | 1 (0.7-1.4)§ |
| None | 12 (3.9%)* | 1 | 1 |
| Occasional | 42 (17.7%)* | 5.4 (2.7-10.7) | 5.1 (2.6-9.9)|| |
| Frequent | 82 (47.4%)* | 22.5 (10.4-48.3) | 11.1 (5.4-22.6)|| |
| Intensive | 153 (67.7%)* | 52.2 (21.7-125.7) | 25.7 (12.5-52.9)|| |
| No | 83 (12.9%)* | 1 | 1 |
| Yes | 206 (67.3%)* | 13.8 (9.3-20.6) | 7.7 (5.4-11.0)|| |
OR – odds ratio, CI – confidence interval
*χ2 test (P < 0.001); Cochran-Armitage test for trend (P < 0.001); only ordinal exposures were tested for trend.
†Likelhood ratio test (P < 0.001); adjusted for the factor age divided by 10.
‡χ2 test (P = 0.23).
§ Likelihood ratio test (P = 0.96); adjusted for age.
||Likelihood ratio test (P < 0.001); adjusted for age and sex.
Frequency of history of Calabar swelling in various strata
| Characteristics | History of Calabar swelling (N = 16)* |
|---|---|
| Below 6 | 0† |
| 6 to 17 | 1 (1.5%)† |
| 18 to 34 | 6 (16.2%)† |
| 35 to 49 | 4 (14.8%)† |
| 50 to 64 | 2 (15.4%)† |
| 65 or older | 3 (11.1%)† |
| Female | 6 (5.4%)‡ |
| Male | 10 (9.9%)‡ |
| None | 4 (6%)§ |
| Occasional | 2 (2.6%)§ |
| Frequent | 3 (7.1%)§ |
| Intensive | 7 (25%)§ |
| No | 4 (2.3%)|| |
| Yes | 12 (28.6%)|| |
*Total of 213 participants included in the Calabar swelling sub-study.
†χ2 test (P = 0.012); Cochran-Armitage test for trend (P = 0.001).
‡χ2 test (P = 0.21).
§χ2 test (P = 0.002); Cochran-Armitage test for trend (P = 0.006).
||χ2 test (P < 0.001).
Factors associated with subsistence activities in the forest
| Characteristics | Subsistence activities in the forest (N = 947) |
|---|---|
| Below 6 | 17 (10.6%)* |
| 6 to 17 | 108 (39.7%)* |
| 18 to 34 | 96 (65.3%)* |
| 35 to 49 | 103 (85.8%)* |
| 50 to 64 | 97 (85.8%)* |
| 65 or older | 119 (88.2%)* |
| Female | 292 (56.9%)† |
| Male | 248 (57.1%)† |
| None | 0* |
| Occasional | 168 (70.9%)* |
| Frequent | 163 (94.2%)* |
| Intensive | 209 (92.5%)* |
| Negative | 293 (44.5%)* |
| Positive | 247 (85.5%)* |
*χ2 test (P < 0.001), Cochran-Armitage test for trend (P < 0.001); only ordinal exposures were tested for trend.
†χ2 test (P = 0.99).
Figure 1Pie chart, demonstrating occupational status of participants.
Figure 2Series of proportional Venn diagrammes showing the overlap of loiasis, pruritus and various degrees of sylvan exposures. From left to right: “No exposure” – no significant activities in the forest; “occasional” – twice per week; “frequent” – daily activities in the forest; “intensive” – daily activities in the deep tropical rain forest.
Performance characteristics of different composite exposures computed from presence of pruritus and sylvan exposure (part 1)
| Regular weekly forest exposure† | 95.8% (92.9-97.8) | 45.4% (41.6-49.3) | 43.6% (39.7-47.5) | 96.1% (93.4-98.0) |
| Occasional forest exposure | 14.5% (10.7-19.1) | 70% (66.7-73.8) | 17.7% (13.1-23.2) | 65.2% (61.6-68.7) |
| Frequent forest exposure | 28.4% (23.2-33.9) | 86.2% (83.3-88.7) | 47.4% (39.8-55.1) | 73.3% (70.0-76.3) |
| Intensive forest exposure | 52.9% (47.0-58.8) | 88.9% (86.3-91.2) | 67.7% (61.2-73.7) | 81.1% (78.1-83.9) |
| (Frequent or intensive) forest exposure | 81.3% (76.3-85.6) | 75.1% (71.6-78.3) | 58.9% (53.9-63.8) | 90.1% (87.3-92.5) |
| Pruritus | 71.3% (65.7-76.4) | 84.8% (81.8-87.5) | 67.3% (61.8-72.5) | 87.1% (84.2-89.6) |
| Pruritus + regular weekly forest exposure | 69.6% (63.9-74.8) | 87.4% (84.6-89.8) | 70.8% (65.1-76.0) | 86.7% (83.9-89.2)* |
| Pruritus + occasional forest exposure | 6.6% (4.0-10.1) | 96.4% (94.6-97.6) | 44.2% (29.1-60.1) | 70.1% (67.0-73.1) |
| Pruritus + frequent forest exposure | 18.3% (14.0-23.3) | 95.9% (94.1-97.3) | 66.3% (54.8-76.4) | 72.8% (69.7-75.7) |
| Pruritus + intensive forest exposure | 44.6% (38.8-50.6) | 95.1% (93.2-96.7) | 80.1% (73.1-86.0) | 79.6% (76.7-82.4) |
| Pruritus + (frequent or intensive) forest exposure | 63% (57.1-68.6) | 91% (88.6-93.1) | 75.5% (69.6-80.8) | 84.8% (82.0-87.4) |
CI – confidence interval, PPV – positive predictive value, NPV – negative predictive value
*NPV of 97.6% (95.1 - 99.0) if both pruritus & regular weekly forest exposure are reported negative.
†“Regular weekly forest exposure” defined as at least twice per week.
Performance characteristics of different composite exposures computed from presence of pruritus and sylvan exposure (part 2)*
| Regular weekly forest exposure | 1.76 (1.63-1.89) | 0.09 (0.05-0.16) | 0.69 (0.68-0.72) | 43.6% (39.7-47.5) | 3.9% (2.0-6.6) |
| Occasional forest exposure | 0.49 (0.36-0.66) | 1.21 (1.13-1.30) | 0.41 (0.38-0.44) | 17.7% (13.1-23.2) | 34.8% (31.3-38.4) |
| Frequent forest exposure | 2.05 (1.57-2.67) | 0.83 (0.77-0.90) | 0.60 (0.56-0.64) | 47.4% (39.8-55.1) | 26.7% (23.7-30.0) |
| Intensive forest exposure | 4.77 (3.75-6.08) | 0.53 (0.47-0.60) | 0.74 (0.71-0.78) | 67.7% (61.2-73.7) | 18.9% (16.1-21.9) |
| (Frequent or intensive) forest exposure | 3.26 (2.83-3.77) | 0.25 (0.19-0.32) | 0.75 (0.72-0.77) | 58.9% (53.9-63.8) | 9.9% (7.5-12.7) |
| Pruritus | 4.69 (3.86-5.70) | 0.34 (0.28-0.41) | 0.77 (0.74-0.81) | 67.3% (61.8-72.5) | 12.9% (10.4-15.8) |
| Pruritus + regular weekly forest exposure | 5.51 (4.45-6.84) | 0.35 (0.29-0.42)† | 0.79 (0.76-0.82) | 70.8% (65.1-76.0) | 13.3% (10.8-16.1)† |
| Pruritus + occasional forest exposure | 1.80 (1.00-3.24) | 0.97 (0.94-1.00) | 0.57 (0.50-0.65) | 44.2% (29.1-60.1) | 29.9% (26.9-33.0) |
| Pruritus + frequent forest exposure | 4.47 (2.87-6.96) | 0.85 (0.80-0.90) | 0.70 (0.64-0.75) | 66.3% (54.8-76.4) | 27.2% (24.3-30.3) |
| Pruritus + intensive forest exposure | 9.18 (6.39-13.18) | 0.58 (0.52-0.65) | 0.80 (0.76-0.83) | 80.1% (73.1-86.0) | 20.4% (17.6-23.3) |
| Pruritus + (frequent or intensive) forest exposure | 7.02 (5.42-9.10) | 0.41 (0.35-0.47) | 0.80 (0.77-0.83) | 75.5% (69.6-80.8) | 15.2% (12.6-18.0) |
LR (+) – likelihood ratio for positive test result; LR (-) – likelihood ratio for negative test result; Post-test p (+) – post-test probability for positive result; Post-test p (-) – post-test probability for negative result, ROC – receiver operating characteristic curve, CI – confidence interval
*N.B.: Pre-test probability for loiasis in the study population = 30.5%.
†LR (-) of 0.06 (0.03-0.12) and post-test p (-) of 2.4% (1-0-4.9) if both pruritus & regular weekly forest exposure are reported negative.